Effects of Neoadjuvant Therapy After the Initial Assessment of Operability in Patients with Borderline Operable and Inoperable Stage IIIA Non-small Lung Cancer.
Adenocarcinoma
/ drug therapy
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
/ methods
Pneumonectomy
/ methods
Retrospective Studies
Treatment Outcome
inoperable cancer
lobectomy
lung cancer
neoadjuvant therapy
pulmectomy
Journal
Medical archives (Sarajevo, Bosnia and Herzegovina)
ISSN: 1986-5961
Titre abrégé: Med Arch
Pays: Bosnia and Herzegovina
ID NLM: 101635337
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
14
10
2021
Statut:
ppublish
Résumé
Lung cancer is a neoplasm with the highest mortality rate in the world. The role of neoadjuvant therapy in patients with initially assessed borderline operable or inoperable lung cancer is to improve survival by downstaging the tumor and allowing surgical resection, as well as the potential treatment of micrometastatic disease. Establishing the justification and efficacy of neoadjuvant therapy after the initial assessment of operability in patients with borderline operable and inoperable histopathologically verified stage IIIA non-small cell lung cancer. The retrospective study included 65 patients with initially assessed stage IIIA lung cancer, who underwent neoadjuvant therapy. After the cycles of neoadjuvant therapy, 19 patients who achieved the regression of the tumor underwent surgery. We analyzed the histological type of the tumor, extent, and prevalence of surgical resection, the status of regional lymph nodes, and the achieved R status. Of the total number of patients who underwent neoadjuvant therapy, after reevaluation of the disease, 19 patients (19/65, 29.23% of cases) achieved a clinical response, i.e. tumor downstaging. Of 19 patients who underwent surgery, 16 patients underwent surgical resection, while three patients underwent surgical exploration. The largest number of patients had N0 and N1 status (six patients each). R0 status was achieved in 14 patients (14/16, 87.5% of cases), while R1 in the remaining two. One patient had a fatal outcome. Neoadjuvant therapy plays an important role in the treatment of initially assessed borderline operable or inoperable lung cancers. By downstaging the tumor, it allows surgical resection and potential treatment of micrometastatic disease.
Identifiants
pubmed: 33424088
doi: 10.5455/medarh.2020.74.350-354
pmc: PMC7780786
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-354Informations de copyright
© 2020 Ilijaz Pilav, Alma Alihodzic-Pasalic, Safet Musanovic, Ademir Hadzismailovic Alen Pilav Kenan Kadic, Orhan Custovic, Meho Dapcevic.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109
pubmed: 30866032
J Clin Oncol. 2005 Feb 1;23(4):924-5; author reply 925-6
pubmed: 15681545
J Clin Oncol. 2010 Apr 10;28(11):1843-9
pubmed: 20231678
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
J Thorac Oncol. 2013 Jul;8(7):915-22
pubmed: 23608815
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
Lung Cancer. 1999 Oct;26(1):7-14
pubmed: 10574676
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Dec;10(12):1675-84
pubmed: 26709477